International application No.

PCT/SE 2005/000010

A. CLASSIFICATION OF SUBJECT MATTE
------------------------------------

IPC7: C07D 239/84, C07D 401/12, C07D 403/12, C07D 409/12, A61K 31/517, A61P 3/04, A61P 25/18, A61P 25/28
According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: CO7D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

#### SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

### EPO-INTERNAL, WPI DATA, PAJ

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
X	WO 03028641 A2 (TAISHO PHARMACEUTICAL CO., LTD.), 10 April 2003 (10.04.2003)	1-12,14-16	
X	J. Med. Chem. volume 36, 1993, Dario Giardinà et al: "Structure-Activity Relationships in Prazosin-Related Compounds. 2.1 Role of the Piperazine Ring on alpha-Blocking Activity2" pages 690-698	16	
	<del></del>		
Ρ,Χ	WO 2004087680 A1 (TAISHO PHARMACEUTICAL CO.,LTD.), 14 October 2004 (14.10.2004)	1-12,14-16	
:			

Х	Further documents are listed in the continuation of Box	. C.	See patent family annex.		
*	Special categories of cited documents:	″T″	later document published after the international filing date or priority		
"A"	document defining the general state of the art which is not considered to be of particular relevance	_	date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive		
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other		step when the document is taken alone		
	special reason (as specified)	"Y"	document of particular relevance: the claimed invention cannot be		
″O″	document referring to an oral disclosure, use, exhibition or other means		considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art		
"P"	document published prior to the international filing date but later than the priority date claimed	"& <u>"</u>	document member of the same patent family		
Date	e of the actual completion of the international search	Date of mailing of the international search report			
4	4 April 2005		2 2 -04- 2005		
Nan	ne and mailing address of the ISA/	Autho	rized officer		
Swe	Swedish Patent Office				
Вох	Box 5055, S-102 42 STOCKHOLM		Eva Johansson/Els		
Facsimile No. +46 8 666 02 86		Telephone No. +46 8 782 25 00			

International application No.
PCT/SE 2005/000010

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No	
х	File EPODOC/EPO, TAISHO PHARMA CO LTD:  "MCH Receptor Antagonist",  JP2004315511,A,20041111	1-12,14-16	
A	WO 9720823 A2 (NOVARTIS AG), 12 June 1997 (12.06.1997)	1-17	

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

International application No.
PCT/SE 2005/000010

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)				
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1. Claims Nos.: 13, 17 because they relate to subject matter not required to be searched by this Authority, namely:				
Claims 13, 17 relate to a method of treatment of the human or animal body by surgery or by therapy, as well as diagnostic				
2.				
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:				
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).				
Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)				
This International Searching Authority found multiple inventions in this international application, as follows:				
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.				
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.				
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:				
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:				
Remark on Protest  The additional search fees were accompanied by the applicant's protest.				
No protest accompanied the payment of additional search fees.				

International application No. PCT/SE2005/000010

D TT 1	
Box II.1 methods /Rule 39.1(iv). Nevertheless, a executed for these claims. The search has alleged effects of the compounds.	search has been been based on the

Form PCT/ISA/210 (extra sheet) (January 2004)

01/03/2005

International application No. PCT/SE 2005/000010

WO	03028641	A2	10/04/2003	CA EP	2460594 A 1432693 A	10/04/2003 30/06/2004
WO	2004087680	A1	14/10/2004	US	20030227750 A	11/12/2003
WO	9720823	A2	12/06/1997	AU Za	7692996 A 9610020 A	27/06/1997 01/06/1997

Form PCT/ISA/210 (patent family annex) (January 2004)